What Is Sermorelin? Benefits, Research & Safety
A truncated form of natural GHRH that was the first GHRH analogue approved for clinical use, used for GH deficiency diagnosis and treatment.
UK summary: Not currently licensed in the UK; the historical FDA-approved version (Geref) was withdrawn. GHRH analogue similar to CJC-1295 but shorter-acting. Prohibited at all times under WADA S2.
Quick Facts
Overview
Sermorelin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not currently licensed in the UK; the historical FDA-approved version (Geref) was withdrawn. GHRH analogue similar to CJC-1295 but shorter-acting. Prohibited at all times under WADA S2.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. May be available through compounding pharmacies.
- EU: Not widely approved; availability varies by country.
- Notes: Sermorelin was FDA-approved but voluntarily withdrawn from the US market. It remains available through compounding pharmacies in some regions. It is prohibited in competitive sports.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Reverses age-related growth-hormone decline in healthy adults.
- Equivalent to HGH replacement without the cost or risks.
- Improves body composition and skin quality in healthy ageing.
- Safe long-term anti-ageing therapy.
07Common internet claims
- Marketed by private 'anti-ageing' clinics as a GH-restoring injection.
- Sold via compounding pharmacies as a daily subcutaneous treatment.
- Promoted as 'natural' GH stimulation compared with synthetic HGH.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “FDA-approved for adult GH deficiency” | B | Yes | Low | Sermorelin had FDA approval (Geref) for paediatric GH deficiency; the product was withdrawn from the US market. It is not currently a licensed UK medicine. |
| “Safer anti-ageing than HGH” | E | No | High | Comparative safety claims need comparative trials. Sermorelin is unlicensed in the UK; HGH is a controlled medicine. |
| “Boosts natural GH for healthy adults” | C | Limited | Moderate | Short-term GH-response data exist; outcomes data in healthy adults are limited. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Injection-site reactions.
- Flushing, headache, nausea.
- Theoretical risks of chronic supraphysiological GH and IGF-1 elevation.
- Unknown long-term cancer-risk implications.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. May be available through compounding pharmacies.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not widely approved; availability varies by country.
15What this page cannot tell you
- Whether a UK-purchased compounded Sermorelin contains the labelled peptide at the labelled concentration.
- What chronic exposure does to insulin sensitivity, organ growth, or oncologic risk.
- Whether it provides benefit in a healthy adult without diagnosed GH deficiency.
- What the WADA in-competition exposure looks like — GH secretagogues are class-prohibited (S2).
16Last reviewed
17Citation quality score
18Research gaps
- No registered Phase 3 trials in healthy adults for anti-ageing endpoints.
- Long-term safety data largely absent.
- Comparative head-to-head trials with HGH or other GH secretagogues are limited.
- Outcome data (lean mass, bone density, quality of life) in healthy ageing is sparse.
19Safer alternatives / established care pathways
- GP and endocrinologist review if adult growth-hormone deficiency is clinically suspected, with ITT or GHRH-arginine testing.
- Licensed recombinant HGH (Genotropin, Norditropin) under endocrinologist supervision where genuine deficiency is confirmed.
- Resistance training and protein-adequate nutrition for body-composition goals in healthy ageing — the only evidence base.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Sermorelin a licensed UK medicine?
- If you suspect adult GH deficiency, what investigations would you do?
- What licensed alternatives exist?
- What is the WADA / UKAD position?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Physiological stimulation of growth hormone release
- 2Elevated IGF-1 levels through natural mechanisms
- 3Maintenance of normal GH pulsatility and feedback
- 4Potential improvements in body composition
- 5Possible enhancement of sleep quality (GH release during sleep)
- 6Lower risk of excessive GH levels compared to direct GH injection
- 7May support pituitary function long-term
Claim vs Evidence
How popular claims about Sermorelin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “FDA-approved for adult GH deficiency” | B | Yes | Low | Sermorelin had FDA approval (Geref) for paediatric GH deficiency; the product was withdrawn from the US market. It is not currently a licensed UK medicine. |
| “Safer anti-ageing than HGH” | E | No | High | Comparative safety claims need comparative trials. Sermorelin is unlicensed in the UK; HGH is a controlled medicine. |
| “Boosts natural GH for healthy adults” | C | Limited | Moderate | Short-term GH-response data exist; outcomes data in healthy adults are limited. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 200-300 mcg per dose (based on historical clinical use) |
| Frequency | Once daily, typically at bedtime |
| Duration | Ongoing; often used long-term for GH optimisation |
| Notes | Sermorelin was previously an approved medication. It is still available through compounding pharmacies in some regions. Use should be under medical supervision with appropriate monitoring of GH and IGF-1 levels. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common)
| Half-Life | Stability |
|---|---|
| Approximately 10-20 minutes | Lyophilised powder stable when properly stored; reconstituted solution should be refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (redness, swelling, pain)
- Flushing immediately after injection
- Headache
- Dizziness
Rare Risks & Concerns
- Antibody formation (reduced efficacy over time)
- Effects on glucose metabolism
- Theoretical concerns shared with all GH-releasing agents
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Hypersensitivity to Sermorelin or GHRH
- Certain brain lesions or tumours affecting the pituitary
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. May be available through compounding pharmacies.
🇪🇺 European Union
Not widely approved; availability varies by country.
Clinical Studies Summary
Sermorelin for Growth Hormone Deficiency
Clinical studies supporting Sermorelin's use in diagnosing and treating GH deficiency in children.
Sermorelin in Adult GH Deficiency
Research on Sermorelin use in adults for GH optimisation.
Looking for Sermorelin?
Source research-grade Sermorelin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Sermorelin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Sermorelin a licensed UK medicine?
- If you suspect adult GH deficiency, what investigations would you do?
- What licensed alternatives exist?
- What is the WADA / UKAD position?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-2
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
Learn moreTesamorelin
An FDA-approved growth hormone releasing hormone analogue used to reduce excess abdominal fat in HIV patients with lipodystrophy.
Learn more